Here's why this biotechnology skyrocketed by 439% in December

A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an ...

Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and ChinaNew ...
FierceBiotech

Taiho’s DMD asset fails to improve functional motor test results in phase 3 trial

Taiho Pharmaceutical’s investigational treatment for Duchenne muscular dystrophy (DMD) has failed to impact the time it takes patients to rise from the floor over 52 weeks, missing the phase 3 study’s ...
FierceBiotech

3 execs resign as Dyne posts mixed data for DMD candidate

After escaping a clinical hold several years back, Dyne Therapeutics has revealed new phase 1/2 data for its Duchenne muscular dystrophy (DMD) therapy DYNE-251. The readout notes several serious ...
FiercePharma

Sarepta reports one death after patient received DMD gene therapy Elevidys

One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech said (PDF) Tuesday. The patient suffered acute ...
Everyday Health

Duchenne Muscular Dystrophy (DMD) Diagnosis

This rare genetic disorder is due to the absence of a vital protein called dystrophin that helps the body maintain muscle cells, which results in rapid muscle degeneration and increasing muscle ...
GEN

DMD Patient Dies After Treatment with Sarepta Gene Therapy

Sarepta Therapeutics said it will update its prescribing information for Elevidys ® (delandistrogene moxeparvovec-rokl) after acknowledging the sudden death of a patient with Duchenne muscular ...